While our prior work demonstrated that Black patients with residual ER + /HER2- disease after neoadjuvant chemotherapy have higher TMEM doorway scores and macrophage levels9, it remains unknown whether these disparities exist at baseline in treatment-naïve breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.